Keros Therapeutics Long Term Debt

Keros Therapeutics (KROS) currently reports a long-term debt of $13M as of June 2026. That compares with $31M in the prior-year period — down 58.3% year over year. Use the charts on this page to explore Keros Therapeutics's long-term debt history and peer comparisons.

Keros Therapeutics's long-term debt decreased from $31M to $13M — a 58.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Keros Therapeutics reported $13M in long-term debt as of June 2026. That compares with $31M in the prior-year period — down 58.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Keros Therapeutics, and consider following KROS for alerts when major investors trade the stock.

Keros Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KROS with unrelated industries.